

Loretta Lau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3914560/publications.pdf>

Version: 2024-02-01

34
papers

3,062
citations

394421

19
h-index

377865

34
g-index

36
all docs

36
docs citations

36
times ranked

6361
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>In vitro</i> and <i>in vivo</i> drug screens of tumor cells identify novel therapies for high-risk child cancer. <i>EMBO Molecular Medicine</i> , 2022, 14, e14608.	6.9	12
2	The C-Circle Biomarker Is Secreted by Alternative-Lengthening-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity. <i>Cancers</i> , 2021, 13, 5369.	3.7	10
3	Recurrent <i>SPECC1L-NTRK</i> fusions in pediatric sarcoma and brain tumors. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005710.	1.2	4
4	“Balancing Expectations with Actual Realities” Conversations with Clinicians and Scientists in the First Year of a High-Risk Childhood Cancer Precision Medicine Trial. <i>Journal of Personalized Medicine</i> , 2020, 10, 9.	2.5	20
5	Parents [™] , Health Care Professionals [™] , and Scientists [™] Experiences of a Precision Medicine Pilot Trial for Patients With High-Risk Childhood Cancer: A Qualitative Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	8
6	Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma. <i>Pathology</i> , 2018, 50, 648-653.	0.6	8
7	The focal adhesion targeting (FAT) domain of p130 Crk associated substrate (p130Cas) confers mechanosensing function. <i>Journal of Cell Science</i> , 2017, 130, 1263-1273.	2.0	10
8	Whole-genome landscape of pancreatic neuroendocrine tumours. <i>Nature</i> , 2017, 543, 65-71.	27.8	716
9	Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> , 2017, 545, 175-180.	27.8	1,068
10	Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. <i>Cell Reports</i> , 2017, 19, 2544-2556.	6.4	75
11	Alternative lengthening of telomeres does exist in various canine sarcomas. <i>Molecular Carcinogenesis</i> , 2017, 56, 923-935.	2.7	11
12	The C-Circle Assay for alternative-lengthening-of-telomeres activity. <i>Methods</i> , 2017, 114, 74-84.	3.8	95
13	Pilot study of a comprehensive precision medicine platform for children with high-risk cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 10539-10539.	1.6	7
14	Epithelial splicing regulatory protein 1 and 2 paralogues correlate with splice signatures and favorable outcome in human colorectal cancer. <i>Oncotarget</i> , 2016, 7, 73800-73816.	1.8	32
15	Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling. <i>Molecular Carcinogenesis</i> , 2015, 54, 841-852.	2.7	13
16	Neuroblastoma, Body Mass Index, and Survival. <i>Medicine (United States)</i> , 2015, 94, e713.	1.0	18
17	Telomere extension by telomerase and ALT generates variant repeats by mechanistically distinct processes. <i>Nucleic Acids Research</i> , 2014, 42, 1733-1746.	14.5	92
18	Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. <i>Journal of Neuro-Oncology</i> , 2014, 119, 17-26.	2.9	29

#	ARTICLE	IF	CITATIONS
19	Abstract B51: Extraction and analysis of genomic DNA from formalin-fixed paraffin-embedded neuroblastoma samples following laser capture microdissection. , 2014, , .		0
20	Detection of alternative lengthening of telomeres by telomere quantitative PCR. <i>Nucleic Acids Research</i> , 2013, 41, e34-e34.	14.5	75
21	Expression of Telomeres in Astrocytoma WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity, and Advanced Clinical Grade. <i>Translational Oncology</i> , 2012, 5, 56-IN4.	3.7	71
22	Loss of Wild-Type ATRX Expression in Somatic Cell Hybrids Segregates with Activation of Alternative Lengthening of Telomeres. <i>PLoS ONE</i> , 2012, 7, e50062.	2.5	64
23	Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. <i>Oncogene</i> , 2009, 28, 2024-2033.	5.9	34
24	Skeletal Langerhans cell histiocytosis in children: Permanent consequences and health-related quality of life in long-term survivors. <i>Pediatric Blood and Cancer</i> , 2008, 50, 607-612.	1.5	42
25	HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. <i>Oncogene</i> , 2008, 27, 997-1003.	5.9	164
26	Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. <i>Oncogene</i> , 2007, 26, 1920-1931.	5.9	34
27	Cutaneous Langerhans cell histiocytosis in children under one year. <i>Pediatric Blood and Cancer</i> , 2006, 46, 66-71.	1.5	90
28	Pulmonary Langerhans cell histiocytosis: A variable disease in childhood. <i>Pediatric Blood and Cancer</i> , 2006, 47, 889-893.	1.5	72
29	Childhood brain tumour information on the Internet in the Chinese language. <i>Child's Nervous System</i> , 2006, 22, 346-351.	1.1	18
30	A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. <i>Clinical Cancer Research</i> , 2005, 11, 672-7.	7.0	51
31	Unrelated cord blood transplant as salvage following non-engraftment of unrelated marrow transplant?. <i>Bone Marrow Transplantation</i> , 2004, 34, 275-276.	2.4	3
32	Factors Influencing Survival in Children With Recurrent Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 227-232.	0.6	47
33	Bone marrow transplantation for paediatric AML in first remission: a systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2002, 29, 843-852.	2.4	45
34	NEUROBLASTOMA: A Single Institution's Experience with 128 Children and an Evaluation of Clinical and Biological Prognostic Factors. <i>Pediatric Hematology and Oncology</i> , 2002, 19, 79-89.	0.8	18